Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| chimeric origin | 4977 | 541502-14-1 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
a chimeric anti-interleukin-6 antibody for treatment of multiple myeloma and renal cell carcinoma; in phase I and phase II clinical trials. It was investigated for its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 but the efficacy and safety of siltuximab in the treatment of COVID-19 were not established.
|
| Dose | Unit | Route |
|---|---|---|
| 37 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 23, 2014 | FDA | JANSSEN BIOTECH | |
| May 22, 2014 | EMA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Immune effector cell-associated neurotoxicity syndrome | 104.71 | 79.19 | 18 | 301 | 5750 | 90622378 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Short stature | 167.14 | 92.86 | 23 | 561 | 417 | 42620334 |
| Spinal instability | 120.35 | 92.86 | 18 | 566 | 595 | 42620156 |
| Cushingoid | 120 | 92.86 | 23 | 561 | 3399 | 42617352 |
| Osteopenia | 106.08 | 92.86 | 23 | 561 | 6255 | 42614496 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Immune effector cell-associated neurotoxicity syndrome | 126.32 | 77.42 | 26 | 544 | 14756 | 110573973 |
| Cytokine release syndrome | 81.75 | 77.42 | 25 | 545 | 70281 | 110518448 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AC11 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors |
| MeSH PA | D000970 | Antineoplastic Agents |
| FDA MoA | N0000191004 | Interleukin-6 Antagonists |
| FDA EPC | N0000191006 | Interleukin-6 Antagonist |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Castleman's disease | indication | 207036003 | DOID:0111157 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Interleukin-6 | Cytokine | ANTIBODY BINDING | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| T4H8FMA7IM | UNII |
| D09669 | KEGG_DRUG |
| 4033374 | VUID |
| N0000190760 | NUI |
| 4033374 | VANDF |
| C1609931 | UMLSCUI |
| CHEBI:750147 | CHEBI |
| CHEMBL1743070 | ChEMBL_ID |
| DB09036 | DRUGBANK_ID |
| 9051 | INN_ID |
| C504234 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7396 | IUPHAR_LIGAND_ID |
| 1535218 | RXNORM |
| 219193 | MMSL |
| 30272 | MMSL |
| d08253 | MMSL |
| 015497 | NDDF |
| 704262001 | SNOMEDCT_US |
| 704263006 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Sylvant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73090-420 | INJECTION, POWDER, FOR SOLUTION | 100 mg | INTRAVENOUS | BLA | 31 sections |
| Sylvant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73090-421 | INJECTION, POWDER, FOR SOLUTION | 400 mg | INTRAVENOUS | BLA | 31 sections |